Publication (2021)
Aoki S, Inoue K, Klein S, Halvorsen S, Chen J, Matsui A, Nikmaneshi MR, Kitahara S, Hato T, Chen X, Kawakubo K, Nia HT, Chen I, Schanne DH, Mamessier E, Shigeta K, Kikuchi H, Ramjiawan RR, Schmidt TC, Iwasaki M, Yau T, Hong TS, Quaas A, Plum PS, Dima S, Popescu I, Bardeesy N, Munn LL, Borad MJ, Sassi S, Jain RK, Zhu AX, Duda DG
Placental growth factor promotes tumor desmoplasia and treatment resistance in intrahepatic cholangiocarcinoma
Gut. 2021 Jan 11:gutjnl-2020-322493.
[Citation: - ] [IF: 23.06 (JCR 2020)]
Wong JSL, Kwok GGW, Tang V, Li BCW, Leung R, Chiu J, Ma KW, She WH, Tsang J, Lo CM, Cheung TT, Yau T.
Ipilimumab and Nivolumab/Pembrolizumab in Advanced Hepatocellular Carcinoma Refractory to Prior Immune Checkpoint Inhibitors.
Journal For Immunotherapy of Cancer 2021 Feb;9(2):e001945.
[Citation: 4 ] [IF:13.75 (JCR 2020)]
Wai Lui DT, Lee CH, Tang V, Fong CHY, Lee ACH, Chiu JWY, Leung RCY, Kwok GGW, Li BCW, Cheung TT, Woo YC, Lam KSL, Yau T
Thyroid Immune-Related Adverse Events in Cancer Patients Treated with Anti-PD1/Anti-CTLA4 Immune-Checkpoint Inhibitor Combination
Endocr Pract. 2021 Feb 10:S1530-891X(21)00030-6.
[Citation: 1 ] [IF: 3.44 (JCR 2020)]
Mou H, Yang QA, Yu L, Wang T, Liu K, Shen R, Pan X, Dai Y, Wan Q, Zhou F, Qian L, Chen D, Yau T , Dong X, Wang X, Wang S.
PD-L1 expression in hepatocellular carcinoma and its correlation with clinicopathological characteristics
J Gastroenterol Hepatol. 2021 Mar 3
[Citation: - ] [IF: 4.03 (JCR 2020)]
Tsang J, Wong JSL, Kwok GGW, Li BCW, Leung R, Chiu J, Cheung TT, Yau T.
Drug Profile: Nivolumab plus Ipilimumab for Patients with Hepatocellular Carcinoma previously treated with Sorafenib
Expert Review of Gastroenterology & Hepatology 2021 Mar 5
[Citation: 2 ] [IF: 3.87 (JCR 2020)]
Dong Y, Wong JSL, Sugimura R, Lam KO, Li B, Kwok GGW, Leung R, Chiu JWY, Cheung TT, Yau T
Cancers (Basel). 2021 Apr 18;13(8):1949.
[Citation: - ] [IF: 6.64 (JCR 2020)]
Wong JS, Dong Y, Tang V, Leung T, Yeung CSY, Tai A, Law A, Shum T, Kwok GG, Li BC, Leung R, Chiu J, Ma KW, She WH, Tsang J, Cheung TT, Yau T
The Use of Cabozantinib in Advanced Hepatocellular Carcinoma in Hong Kong—A Territory-Wide Cohort Study
Cancers (Basel). 2021 Apr 21;13(9):2002.
[Citation: - ] [IF: 6.64 (JCR 2020)]
Wiedermann U, Garner-Spitzer E, Chao Y, Maglakelidze M, Bulat I, Dechaphunkul A, Arpornwirat W, Charoentum C, Yen CJ, Yau T, Tanasanvimon S, Maneechavakajorn J, Sookprasert A, Bai LY, Chou WC, Ungtrakul T, Drinić M, Tobias J, Zielinski CC, Chong L, Ede NJ, Marino MT, Good AJ.
Characterization of clinical and immunologic responses to a novel HER2/neu B-cell epitope 2 vaccine in HER2/neu overexpressing advanced gastric cancer patients – results from Phase 3 1b trial IMU.ACS.001
Clin Cancer Res. 2021 Apr 20
[Citation: - ] [IF: 12.53 (JCR 2020)]
Wong CY, Leung R, Kwok GW, Tsang J, Li B, Yau T, Chiu J.
Safety and tolerability of subcutaneous trastuzumab and intravenous pertuzumab as adjuvant treatment for HER2 positive breast cancer
Postgrad Med J. 2021 May 26. doi:10.1136/postgradmedj-2021-140319
[Citation: -] [IF: 2.40 (JCR 2020)]
Kudo M, Lim HY, Cheng AL, Chao Y, Yau T, Ogasawara S, Kurosaki M, Morimoto N, Ohkawa K, Yamashita T, Lee KH, Chen E, Siegel AB, Ryoo BY.
Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial
Liver Cancer. 2021 Jun;10(3):275-284
[Citation: - ] [IF: 11.74 (JCR 2020)]
Qin S, Ren Z, Feng Y, -H, Yau T, Wang B, Zhao H, Bai Y, Gu S, Li L, Hernandez S, Xu D, -Z, Mulla S, Wang Y, Shao H, Cheng A, L
Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study
Liver Cancer (In Press) 2021. doi: 10.1159/000513486
[Citation: - ] [IF: 11.74 (JCR 2020)]
Kelley RK, Sangro B, Harris W, Ikeda M, Okusaka T, Kang YK, Qin S, Tai DW, Lim HY, Yau T, Yong WP, Cheng AL, Gasbarrini A, Damian S, Bruix J, Borad M, Bendell J, Kim TY, Standifer N, He P, Makowsky M, Negro A, Kudo M, Abou-Alfa GK.
Efficacy and Tolerability of Novel Regimen of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study
J Clin Oncol. 2021 Jul 22
[Citation: - ] [IF: 44.54 (JCR2020)]
Ho Yin Chung, Shirley Chiu Wai Chan, Eva Tsz Fung Chui, Thomas Chung Cheung Yau, Chak Sing Lau
Malignancies in patients with spondyloarthritis with and without concomitant psoriasis, and the effect of disease modifying anti-rheumatic drugs
Clinical and Experimental Rheumatology (In Press)
[Citation: - ] [IF: 3.32 (JCR2020)]
Tim F. Greten, Ghassan K. Abou-Alfa, Ann-Lii Cheng , Austin G. Duffy , Anthony B. El-Khoueiry, Richard S. Finn , Peter R. Galle, Lipika Goyal, Aiwu Ruth He, Ahmed O. Kaseb, Robin Kate Kelley , Riccardo Lencioni, Amaia Lujambio, Donna Mabry Hrones, David J. Pinato, Bruno Sangro, , Roberto I. Troisi Andrea Wilson Woods, Thomas Yau, Andrew X. Zhu, , Ignacio Melero
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma
Journal For Immunotherapy of Cancer (In Press)
[Citation: - ] [IF: 13.75 (JCR 2020)]
Arndt Vogel; Philippe Merle; Chris Verslype; Richard S. Finn; Andrew X. Zhu; Ann-Lii Cheng; Stephen Lam Chan; Thomas Yau; Baek-Yeol Ryoo; Jennifer Knox; Bruno Daniele; Shukui Qin; Ziwen Wei; Yanna Miteva; Usha Malhotra; Abby B. Siegel; Masatoshi Kudo
Baseline Liver Function and Outcomes in Patients With Unresectable Hepatocellular Carcinoma Enrolled in a Randomized, Double-Blind, Phase 3 Study (KEYNOTE-240)
Therapeutic Advances in Medical Oncology (In Press)
[Citation: - ] [IF: 8.17 (JCR 2020)]
Li BC, Chiu J, Shing K, Kwok GG, Tang V, Leung R, Ma KW, She WH, Tsang J, Chan A, Cheung TT.
The Outcomes of Systemic Treatment in Recurrent Hepatocellular Carcinomas Following Liver Transplants.
Advances in Therapy. 2021 Jun 1:1-1.
[Citation: - ] [IF: 3.85 (JCR 2020)]